Technology Is Reshaping Sleep Apnea Treatment

Inspire therapy has been FDA-approved and treated over 100,000 patients, inspire therapy has been FDA-approved for over 11 years and treated over 100,000 patients across the US, Europe, and Asia.

Inspire therapy data show reductions in sleepiness, apnea severity, and snoring, clinical data reported reductions in daytime sleepiness, a 79 percent drop in sleep apnea severity, and a 90 percent reduction in snoring for Inspire patients.

Inspire therapy had average nightly usage exceeding 6.5 hours in early US data, early US data report average nightly usage of Inspire devices of more than 6.5 hours.

FDA approved Zepbound (tirzepatide) for OSA in adults with obesity in 2024, the FDA approved Zepbound (tirzepatide) in 2024 for moderate to severe obstructive sleep apnea in adults with obesity.

Apnimed developed a nightly drug targeting neuromuscular pathways for upper airway tone, apnimed developed a nightly pill that targets neuromuscular pathways to influence upper airway tone.